Skip to main content

What the FDA labels say about taking them together

Cabazitaxel and clarithromycin

Cabazitaxel's FDA label of October 7, 2025 names clarithromycin in its drug interactions section; the clarithromycin label PlainMeds reads does not name cabazitaxel. The cabazitaxel label: “Strong CYP3A inhibitors may increase plasma concentrations of cabazitaxel.”

Check it at the source: the cabazitaxel FDA label on DailyMed (effective October 7, 2025, Sanofi-Aventis U.S. LLC); the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation).

What does the cabazitaxel label say about clarithromycin?

Cabazitaxel label, drug interactions

Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase plasma concentrations of cabazitaxel.

Source: FDA drug label (Jevtana), Sanofi-Aventis U.S. LLC, effective October 7, 2025 (SPL set de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa), via openFDA; the full label on DailyMed

What does the clarithromycin label say about cabazitaxel?

Clarithromycin's label (effective April 9, 2026) does not name cabazitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Cabazitaxel generic labelers
26Clarithromycin generic labelers
CabazitaxelClarithromycin
Labeled forProstate cancerBacterial infections, Acid reflux and ulcers
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.466 per tablet 500 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?